The following content is for informational purposes only. This article is not intended to be a substitute for profession ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Whenever a new year begins, most of us strive to make some resolutions such as going to the gym, drinking less (aka, Sober ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...